头颈鳞状细胞癌靶向治疗现状及进展  

Current status and progress of targeted therapy for head and neck squamous cell carcinoma

作　　者：阮林[1] 林小峰 黄素宁 韦力[3] Ruan Lin;Lin Xiaofeng;Huang Suning;Wei Li(Radiotherapy Department,The First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China;Radiotherapy Department,Guangxi Medical University Affiliated Tumor Hospital,Nanning 530021,China;Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学第一附属医院放疗科,南宁530021 [2]广西医科大学附属肿瘤医院放疗科,南宁530021 [3]广西医科大学,南宁530021

出　　处：《广西医科大学学报》2020年第5期972-976,共5页Journal of Guangxi Medical University

基　　金：国家自然科学基金(No.81460479);广西自然科学基金项目(No.901088162022)。

摘　　要：头颈鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)是人体较常见的恶性肿瘤之一,复发或转移是制约其预后的重要因素。传统治疗方式已到达瓶颈期,靶向药物的出现为复发或转移性头颈鳞状细胞癌的治疗带来新的方向。表皮生长因子受体抑制剂单克隆抗体、酪氨酸酶抑制剂、抗血管生成制剂、环氧化酶-2抑制剂等已日益广泛应用于临床,本文将综述HNSCC靶向治疗的现状及相关进展。Head and neck squamous cell carcinoma(HNSCC) is one of the most common malignant tumors in human body, andrecurrence or metastasis is an important factor restricting its prognosis. The traditional treatment has reached the bottleneck stage, and the targeted drug brings a new direction for the treatment of recurrent or metastatic of HNSCC. Epidermal growth factor receptor inhibitor monoclonal antibody, tyrosinase inhibitor, antiangiogenesis agent, and cyclooxygenase-2 inhibitor and so on have been widely used in clinical. This article will review the current status and related progress of HNSCC targeted therapy.

关 键 词：头颈鳞状细胞癌 靶向药物 靶向治疗 

分 类 号：R739.91[医药卫生—肿瘤]